Neurology
Cataplexy Is Waiting on an FDA Clock
FDA has accepted Axsome’s NDA for AXS-12 in cataplexy associated with narcolepsy. The review is now formal, but approval, access and specialist recognition are still unresolved.
A Urine Test for Alzheimer’s Would Change the Access Conversation
AlphaGenome Makes Variant Interpretation Political
AI Diagnosis Has Entered the Access Debate
AI in Cardiology Moves From Promise to Policy Pressure
Cyberbullying Becomes a Youth Mental Health Policy Target
Alzheimer’s Agitation Gets a New Drug, But Care Pathways Still Lag
Rare Epilepsy Moves Toward Treating the Cause
Huntington Gene Therapy Hits the Evidence Wall
Rare Disease Policy Moves Into the Individualised Therapy Era
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.